Strategic Partnerships Orsini already acts as exclusive or preferred partner for Denali Therapeutics' AVLAYAH therapy for MPS II and collaborates with Glaukos, Immedica, and others. This demonstrates a proven model for co marketing, patient access programs, and specialized distribution that can be extended to new rare disease therapies and enzyme replacement therapies. BD opportunities include pursuing joint patient access programs, regulatory support, and outcome data collaboration with sponsors.

High Touch Care Orsini's high touch care model combines therapy specific care teams, in home infusion nursing coverage, medication adherence programs, and data analytics. These capabilities reduce patient friction, improve adherence, and provide a compelling value proposition to biopharma sponsors seeking strong patient engagement and post launch support. Leverage ORBIT Track to improve partner coordination and visibility across patient journeys.

Integrated Logistics Orsini's integrated specialty pharmacy and 3PL solution and national footprint, including a Columbus facility, demonstrate end to end readiness for national launches, trial supply, and complex logistics. This supports rapid patient onboarding and reliable distribution for new rare disease therapies across markets. Use in pitches to sponsors planning multi state rollouts and international patient programs.

Compliance Trust ACHC and NABP accreditations along with HIPAA compliance provide credibility with payers, health systems, and providers. Use these credentials to win contracts for complex therapies, support regulatory submissions and pharmacovigilance, and negotiate favorable payer terms or risk-sharing arrangements.

Scale and Momentum The company's size and ongoing partnerships indicate a scalable platform capable of absorbing larger deals across multiple disease areas. This positions Orsini as a reliable long term partner for multi therapy launches, bundled solutions, and integrated care programs with biopharma sponsors seeking consolidation.